Journal
MODERN RHEUMATOLOGY
Volume 21, Issue 1, Pages 92-96Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1007/s10165-010-0348-9
Keywords
Adult-onset Still's disease; Tocilizumab; Macrophage-activation syndrome; Hemophagocytic lymphohistiocytosis
Categories
Ask authors/readers for more resources
We report a 57-year-old female case of intractable adult-onset Still's disease (AOSD). Initial high-dose prednisolone therapy was ineffective, and macrophage-activation syndrome (MAS) manifested after one session of additional tocilizumab therapy. After successful treatment for MAS with lipo-dexamethasone and cyclosporin, tocilizumab therapy aided in the rapid reduction of the therapeutic steroid dose. Tocilizumab may be useful for maintenance therapy for AOSD, although its efficacy is unclear for the highly active phase of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available